Venaxis Inc news

   Watch this stock
Showing stories 1 - 10 of about 20   

Articles published

APPY 1.61 +0.01 (0.45%)
price chart
Venaxis to Present at September Investor Conferences
28, 2014 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1� Test, a rapid blood test for aiding in identifying children, adolescent, and young ...
Related articles »  
Eye Catching Stocks: Hertz Global (NYSE:HTZ), BlackBerry (NASDAQ:BBRY ...
BlackBerry Ltd (NASDAQ:BBRY) return on investment (ROI) is -8.45% while return on equity (ROE) is -8.67%. Venaxis, Inc. (NASDAQ:APPY) on Monday shares closed at $1.68. Venaxis, Inc. (NASDAQ:APPY) monthly performance stands at -5.08% while its ...
Morning Buzz: OXiGENE (NASDAQ:OXGN), Pluristem Therapeutics (NASDAQ ...
On 28 AUG Venaxis, Inc. (NASDAQ:APPY) announced it will present at three upcoming investor conferences: the Rodman & Renshaw 16(th) Annual Global Investment Conference being held in New York on September 8-10, 2014, the Aegis Capital 2014 ...
Investors Watch List: AbbVie Inc. (NYSE:ABBV), CEMEX, S.A.B. de C.V. (NYSE ...
Venaxis, Inc. (NASDAQ:APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1� Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the ...
Why Need to Watch: Cavium (NASDAQ:CAVM), Amgen (NASDAQ:AMGN ...
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the ...
Related articles »  
MedX Health Corp. Announces Second Quarter 2014 Financial Results
MISSISSAUGA, ONTARIO -- (Marketwired) -- 08/28/14 -- MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE:MDX), dedicated to the early detection of skin cancer, announced its results for the three and six months ended June 30, 2014, which are ...
Related articles »  
Venaxis closes public offering of common shares
Venaxis prices $20 mln public offering of common shares